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Abstract
A variety of commercial analogs and a newer series of Sulindac derivatives were screened
for inhibition of M. tuberculosis (Mtb) in vitro and specifically as inhibitors of the essential
mycobacterial tubulin homolog, FtsZ. Due to the ease of preparing diverse analogs and a
favorable in vivo pharmacokinetic and toxicity profile of a representative analog, the Sulin-
dac scaffold may be useful for further development against Mtb with respect to in vitro bac-
terial growth inhibition and selective activity for Mtb FtsZ versus mammalian tubulin.
Further discovery efforts will require separating reported mammalian cell activity from both
antibacterial activity and inhibition of Mtb FtsZ. Modeling studies suggest that these ana-
logs bind in a specific region of the Mtb FtsZ polymer that differs from human tubulin and, in
combination with a pharmacophore model presented herein, future hybrid analogs of the
reported active molecules that more efficiently bind in this pocket may improve antibacterial
activity while improving other drug characteristics.
Introduction
Tuberculosis (TB), caused byMycobacterium tuberculosis (Mtb), is one of the most prevalent
infectious diseases worldwide. A recent report by theWorld Health Organization (WHO)
reveals that in 2014 there were an estimated 9.6 million new cases of TB (12% co-infectedwith
HIV) and 1.5 million people died from the disease, including 1.1 million deaths among HIV-
negative individuals and 400,000 among people who were HIV-positive.[1] Moreover, the
increasing development of multi-drug resistant TB (MDR-TB) strains, forms of TB that do not
respond to standard front line regimens, is a serious burden on public health systems through-
out the world. More recently, extensively drug resistant tuberculosis (XDR-TB) that is also
resistant to second line drugs has emerged in numerous areas. These stark realities emphasize
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the acute need for constant reinvention of the anti-TB drug pipeline targeting novel, alternative
drug pathways.[2–3]
New targets for tuberculosis are regularly being identified from existing genomic data and
new screening techniques.[3] The bacterial tubulin homolog, FtsZ (Filamenting temperature-
sensitive protein Z), is essential for bacterial cell division and is an ideal target for novel antimi-
crobials. In recent years, FtsZ has received considerable attention for the discovery of novel
antibacterial and anti-TB drugs.[4–17]
In our search for new active scaffolds againstMtb FtsZ, a variety of small molecules reported
to have antibacterial activity, and, furthermore, some of which were considered to inhibitMtb
or other bacterial FtsZs were acquired and screened for both antitubercular activity andMtb
FtsZ inhibition. A consistent set of antibacterial activity data in parallel with FtsZ screening
results should be useful to prioritize active scaffolds for new analog optimization. Furthermore,
the potent combination of a new crystal structure and these activity data will allow advance-
ment of robust consensus binding models that should help medicinal chemists enhance selec-
tive activity against the bacterial protein target and whole bacteria while potentially
minimizing off-target effects against the direct mammalian homolog, tubulin, as well as reduc-
ing mammalian toxicity through other off-target activities. Beyond the aforementioned anti-
bacterial/FtsZ actives or related compounds, we were particularly intrigued by the reported
similarities of certain non-steroidal anti-inflammatory drugs (NSAIDs), e.g. Indomethacin and
Sulindac analogs, to the known tubulin polymerization inhibitor Colchicine.[18,19]Colchicine
has been reported to be one of the few known tubulin inhibitors that demonstrates activity
againstMtb FtsZ.[15] Sulindac belongs to this chemically diverse group and, importantly, is
not overtly toxic in vivo but shows clinical efficacy for longer term treatment regimens in can-
cer chemoprevention.[20–23] The NSAIDs are excellent pharmacophores showing good activ-
ity through animal models and in the clinic for numerous indications. As part of an ongoing
program to study the chemical biology of interesting NSAID scaffolds such as Sulindac, we
have investigated a variety of analogs and their on-target (COX-1 and 2) and off-target (e.g.
cell cytotoxicity, PDE5, PDE10A) activities.[24–25]Among the interesting and atypical activi-
ties of the NSAIDs, certain known drugs (e.g. Ibuprofen, Aspirin) have been reported to show
antibacterial activity.[26–30] An indomethacine analog closely related to sulindac sulfide
amide (SSA) has been reported to inhibit tubulin polymerization in vitro in a dose response
manner.[18] Hence, we added this early lead Sulindac analog to our initial anti-TB/FtsZ assays
and confirmed that it is a modest potency inhibitor ofMtb FtsZ while showing no inhibition of
human tubulin at 100 μM concentration. The activity of this initial lead warrants the explora-
tion of new sulindac analog series against FtsZ. Herein, we report the screening of a number of
acquired and synthesized samples and a lead Sulindac analog available in our labs against FtsZ
fromM. tuberculosis. These compounds advanced in a series of assays depending on activity
that includeMtb FtsZ,MtbH37Ra, MAC NJ211 and/orMtbH37Rv, tubulin polymerization,
and in a preliminary cell cytotoxicity assay against BJ cells, an immortalizednormal human
foreskin fibroblast cell line. In addition to the presented structure-activity development of the
Sulindac scaffold, we also followed up a potent and previously reported screening hit, Zantrin
Z2, which showed potent activity in our preliminary screens (see S1 Appendix in Supporting
Information for results).
Materials and Methods
Animal ethics statement
All experimental protocols were approved with written consent by the Animal Care and Use
Committee of Colorado State University (approval number ACUC no. 12-3723A), which
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abides by the USDA AnimalWelfare Act and the Public Health ServicePolicy on Humane
Care and Use of Laboratory Animals.
Animal care and euthanasia
The CSU animal assurance welfare number is A3572-01 under file with NIH. All animals are
cared for by the Colorado State Lab Animal Resources, headed by two experiencedveterinari-
ans and a large number of support staff. The mice are observed twice daily by our Research
Associates and Lab Animal Resources (LAR) personnel. A log is kept recording any untoward
behavior. Sick animals are reported to the Staff Veterinarian on a morbidity form. Investigators
receive a copy of the morbidity form with initial physical exam findings, diagnostics, and possi-
ble diagnoses. The LAR at Colorado State University has procedures in place to control animal
pain. Specific health and comfort parameters (activity and temperament, feeding behavior,
appearance) are used to monitor pain and severity of disease of M. tuberculosis infectedmice,
and these conditions are monitored daily to determine the condition of the mice.When issues
are evident (distress, severe physiologic changes, weight loss), mice are required to be eutha-
nized within the day. The method used for euthanasia of mice is carbon dioxide inhalation.
This method, approved by the CSU RegulatoryCompliance Office uses either tank CO2 or
house CO2 This method is approved by the AVMA Panel of Euthanasia, and was chosen for its
reliability, ease of use, and minimization of distress to animals.
Chemical synthesis of sulindac analogs
Compounds 18–43 were synthesized by the coupling of commercially available Sulindac sul-
fide or a new 1-benzothiazolyl Sulindac derivative (prepared from 2-(5-fluoro-2-methyl-1H-
inden-3-yl)acetic acid and benzothiazole-2-carboxaldehyde according to a literature proce-
dure)[31] with various amines using either HBTU[32] or HATU[33] as the coupling agent
(Fig 1).
Preparation of α-methyl Sulindac sulfide amide began with esterification of commercially
available Sulindac sulfide in the presence of MeOH/thionyl chloride to provide Sulindac sulfide
methyl ester in quantitative yield. The introduction of a methyl group at the α-position of the
ester group was carried out using LDA and CH3I to afford α-methyl Sulindac sulfide ester in
93% yield as a mixture of enantiomers.[34] α-Methyl Sulindac sulfide ester was hydrolyzed to
give the corresponding acid in excellent yield. Finally, the coupling of α-methyl Sulindac sul-
fide with various amines in the presence of HATU[33] as the coupling agent afforded
Fig 1. Synthetic pathways to analogs 18–43. Reagents and conditions: (a) HBTU or HATU, TEA or DIEA,
MeCN.
doi:10.1371/journal.pone.0164100.g001
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compounds 44–55 in good yields (Fig 2). Typically, when the racemic mixture of the acid was
treated with a chiral amine, an inseparable mixture of diastereomeric amides was formed.
N,N’-Dimethylaminoethyl amides of Sulindac sulfide and α-methyl Sulindac sulfide (23,
48) were treated with Boc-L-Valine under the same coupling reaction conditions described in
Fig 1 and Fig 2 followed by treatment with acid for the removal of the Boc protecting group to
produce 56–57 in good yields (Fig 3).
The synthetic strategy used to prepare the target compounds 58–60 is outlined in Fig 4. Syn-
thesis began with the esterification of Sulindac sulfide to form its methyl ester. The ester was
then converted to its corresponding aldehyde by treating with DIBALH. Finally, reductive ami-
nation of the aldehyde with various substituted amines afforded compounds 58–60 in moder-
ate yields.[35]
Compounds 61–63 were prepared by methods given above (Fig 1).[31, 32] Further synthetic
experimental details are provided in S2 Appendix under Supporting information.
Compounds. All compounds were purchased commercially (Aldrich, ChemBridge, or
CalBiochem) and used as provided excepting the Sulindac analogs that were prepared as
Fig 2. Synthetic pathways to analogs 44–55. Reagents and conditions: (a) MeOH, SOCl2 (b) LDA. MeI, THF,
−78˚C (c) KOH, EtOH/H2O (d) HATU, DIEA, MeCN.
doi:10.1371/journal.pone.0164100.g002
Fig 3. Synthetic pathways to analogs 56–57. Reagents and conditions: (a) HBTU or HATU, TEA or DIEA,
MeCN (b) H+.
doi:10.1371/journal.pone.0164100.g003
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described earlier (see also Supporting Information). Sanguinarine and Pseudojatorrhizine were
provided by the University of Mississippi National Center for Natural Product Research, and
Totarol was a kind gift of Industrial Research Limited (New Zealand).
Biological studies
In vitro screen versusMtbH37Ra andMAC NJ211. The initial screening set and selected
other compounds were tested for their inhibitory activity againstMtbH37Ra (ATCC 25177)
and MAC NJ211 strains. Screeningwas performed at 1.28 and 12.8 μg/mL in Middlebrook
7H9 broth supplemented with 0.2% glycerol and ADC enrichment using a colorimetric (Ala-
mar blue) microdilution broth assay by reportedmethods.[15] Active compounds (12.8 μg/
mL) were re-tested using twofold dilutions to obtain the actual MIC99. The MIC99 is defined as
the lowest drug concentration that completely inhibited growth.
In vitro qHTS assay againstMtbH37Rv and cytotoxicity evaluations. The Sulindac set
was screened againstMtbH37Rv to determine the IC90 (the concentration that inhibits bacte-
rial growth by 90%) by reportedmethods.[36] These compounds were also counter screened at
St. Jude Children’s Research Hospital for a comparative toxicity assessment against an estab-
lishedmammalian cell line relative to the in vitro MtbH37Rv results. BJ, a normal human fore-
skin fibroblast cell line was purchased from the American Type Culture Collection,ATCC,
Manassas, VA, USA and was cultured according to recommendations.[37] Cell culture
mediumwas also purchased from ATCC. Cells were routinely tested for mycoplasma contami-
nation using the MycoAlert Mycoplasma DetectionKit (Lonza). Approximately 1,000 BJ expo-
nentially growing cells were plated per well (30 μL) in white polystyrene flat bottom sterile
384-well tissue culture treated plates (Corning, Tewksbury, MA, USA), and incubated over-
night at 37°C in a humidified 5% CO2 incubator. Compound solutions (DMSO) were pin-
transferred (V&P Scientific, San Diego, CA, USA) the following day. Cytotoxicity was deter-
mined following a 72-hr incubation of BJ cells with each compound at a concentration of
10 μM using Promega Cell Titer Glo Reagent according to the manufacturer’s recommenda-
tions. Luminescencewas measured on an Envision plate reader (Perkin-Elmer).
Inhibition ofMtb FtsZ polymerization in vitro. Selected available compounds that were
active in vitro againstMtbH37Rv were examined for their ability to inhibit the hypothetical tar-
get,Mtb FtsZ, and its mammalian homolog tubulin using methods describedpreviously.[15]
Compounds were initially screened at 100 μM in duplicate. Those that showed<20% activity
at this concentration were deemed inactive. All other samples ( 20% inhibition) were
screened in a dose response format to obtain IC50 values. Any compounds that were insoluble
Fig 4. Synthetic pathways to analogs 58–60. Reagents and conditions: (a) MeOH, SOCl2 (b) DIBALH,
Toluene (c) NaBH4, MeOH, rt.
doi:10.1371/journal.pone.0164100.g004
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in the assay medium at  25 μM did not advance. Compounds considered active in theMtb
FtsZ assay were further screened in a tubulin polymerization assay as reported.[15]
In vitro Z-ring inhibition Studies: Bacterial strains and growth conditions. Construc-
tion ofM. tuberculosis 41 (Mtb 41) FtsZ reporter strain was previously described.[38] It is a
MtbH37Ra derivative strain where the chromosomal ftsZ is deleted by homologous recombina-
tion and contains a copy of Pami::ftsZ-gfp. The ftsZ-gfp in this strain is expressed from the ami-
dase promoter (Pami) and the reporter strain requires 0.2% acetamide for growth.[38]Mtb 41
was grown in Middlebrook 7H9 broth supplemented with oleic acid, albumin, dextrose,
sodium chloride and 0.2% acetamide. In some experiments, actively growing cultures ofMtb
41 were exposed to the small-molecule inhibitors at 75 μM (ca. the H37RaMIC99) and growth
was followed for several days after exposure by monitoring the absorbance at 600 nm.
Microscopy. M. tuberculosis 41 strain was grown as described in the absence or presence
of the Sulindac analogs for 72 hours, at indicated time points samples were harvested by centri-
fugation, washed in phosphate-buffered saline, fixed in 1% paraformaldehyde, and stored at
4°C until microscopy. Bacteria were examined by bright-field and fluorescencemicroscopy
with a Nikon E600 microscope equipped with a 100X Nikon Plan Fluor oil immersion objec-
tive with a numerical aperture of 1.4 and a standard FITC filter set from Chroma. Images were
acquired with a Photometrics Coolsnap ES camera and MetaMorph 6.2 imaging software (Uni-
versal Imaging Corporation). Images were optimized with Adobe Photoshop CS5.
Computational methods
TheMtb FtsZ crystal structure (PDB code 1RLU) determined at 2.08 Å resolution was refined
applying Prime preparation and refinement tools of the Protein preparation wizard as imple-
mented in Schrödinger software. After the addition of hydrogens and detection of disulfide
bonds the structure was optimized applying default parameters of the Impref utility using the
OPLS2001 force field. The maximum allowed root-mean-square deviation between the refined
structure and the input crystal structure was 0.3. Ligand structures were prepared using the
LigPrep utility at pH 7.4. Ligands were docked into the interdomain cleft site using Induced Fit
docking protocol in XP precision mode. Default parameters were applied except for setting the
site enclosing box size to 33 Å. The Induced Fit dockingmethod combines Glide dockingwith
Prime structural refinement tools in the Schrödinger software to account for the flexibility of
protein side chains within 5 Å of the ligand during docking.
Results and Discussion
A structurally diverse compound set selected for screening
A diverse set of compounds and natural products was selected for screening againstMtb FtsZ
and its mammalian homolog tubulin. In order to assess whole bacterial activity, MICs against
the non-pathogenic mycobacterial strainsMtbH37Ra and MAC NJ211 were determined and
inhibitory activities evaluated against a potential target, FtsZ, that is highly homologous
betweenMtb strains and essential in mycobacteria. Selected results and structures are given in
Table 1 and Fig 5, respectively.
Colchicine was included as a known, albeit modest, inhibitor ofMtb FtsZ.[15] Rhein, Quer-
cetin,Myrcetin, Tetracycline, and Minocycline (Aldrich Chemical Company) contain planar
aromatic systems and bear resemblance to Viriditoxin,[39] a reported natural product that is
active against E. coli FtsZ. Rhein and the isoflavones have also been reported to have antibacte-
rial/antitubercular activity.[40] The Zantrins (Z1-5) were first reported by Margalit as inhibi-
tors of bacterial FtsZ GTPase activity.[11] Z1-Z4 purchased from ChemBridgewere included
as a test to determine how well the reported GTPase activity correlates with inhibition of FtsZ
Screening and Development of New FtsZ Inhibitors for M. Tuberculosis
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polymerization as there is an apparent kinetic disconnect betweenGTPase effects and inhibi-
tion of polymerization.[41] In some respects, Zantrin Z2 is similar to the aromatic cationic
compounds Sanguinarine and Pseudojatorrizine. Sanguinarine has been reported to show anti-
bacterial activity and to inhibit E. coli FtsZ assembly.[42] Tamoxifen is a known antiestrogen
drug that has effects on human tubulin and is reported to show antitubercular activity in a
screen of the Prestwick collection of natural products and FDA approved drugs (see http://
pubchem.ncbi.nlm.nih.gov).[43] Compound 12, a 4-aminofurazan analog available from
ChemBridge, is a reported inhibitor of E. coli FtsZ GTPase activity as well as protein polymeri-
zation in a standard light scattering assay.[44] Compound 12 is also reported to alter Z-ring
assembly in whole bacterial cells and to cause bacterial filamentation in E. coli cells.[44] Totarol
is a reported natural product that inhibits proliferation of a variety of bacteria and is reported
to have activity againstMtb FtsZ in vitro as well as causing bacterial filamentation although
recently reported as a promiscuous aggregator.[9,45] The taxanes are known drugs that alter
tubulin polymerization dynamics, and analogs have been reported to show inhibition ofMtb
growth in vitro and are reported to show specificity forMtb FtsZ.[8] CompoundAG-825 is a
known inhibitor of HER-2 available from Calbiochem, and the compound bears striking
resemblance to a reported class of bacterial FtsZ inhibitors out of the Stokes laboratory.[46]
Table 1. Mtb FtsZ, tubulin and Mtb H37Ra data of selected compounds 1–18.
Entry Name Mtb FtsZ Polymerization IC50
(μM)a
Tubulin Polymerization IC50
(μM)a
Mtb H37Ra MIC99 (μg/
mL)b
MAC NJ211 MIC99 (μg/
mL)
1 Colchicine 104.4 ± 2.0 6.5 ± 0.9 >64 >64
2 Rhein 44.6 ± 6.3 NA 32 (112.66)b >128
3 Quercetin dihydrate 21.7 ± 4.8 NA >128 >128
4 Myrcetin 42.4 ± 6.3 NA >128 >128
5 Tetracycline 87.1 ± 10.7 NA 1 ND
6 Minocycline 37.3 ± 4.6 NA 0.5 ND
7 Zantrin Z4 NA 77.0 ± 3.0 64 >64
8 Zantrin Z2 3.50 ± 0.3 NA 1 (2.05)b 1
9 Pseudojatrorrhizine 105.0 ± 32.0 NA >64 64
10 Sanguinarine Cl•
H2O
23.0 ± 4.0 30.0 ± 7.0 64 (192.58)b >64
11 Tamoxifen citrate 40.6 ± 17.9 NA 8 (21.53)b 32
12 ChemBridge
5481893
33.4 ± 3.0 NA 64 (202.47)b >64
13 Totarol 47.5 ± 4.9 NA 25 (87.27)b 25
14 Taxol NA ND 16 ND
15 AG-825 31.7 ± 1.7 NA ND ND
16 Zantrin Z3 NA NA 1 2
17 Zantrin Z1 NA NA 8 16
18 SRI 21009 39.4 ± 4.9 NA 8 (19.49)b 16
STD* Ethambutol ND ND 2–4 4–8
aEach compound was analyzed at least three times per assay and the mean ± the standard deviations are reported.
ND = not done.
NA = not active up to 100 μM.
bConcentration in μM provided in parentheses for selected actives.
*STD = Ethambutol antitubercular antibiotic standard.
Albendazole (not included above) is a vermicidal that binds to the colchicine site of parasite tubulin inhibiting polymerization into microtubules—NA in the
FtsZ polymerization assay.
doi:10.1371/journal.pone.0164100.t001
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New analog series based on the Sulindac scaffold
We found that SSA (18), an early sulindac analog shows modest inhibition ofMtb FtsZ poly-
merization, inhibits bacterial growth but has no effect on human tubulin at 100 μM (Table 1).
Further we exploredMtb FtsZ activities of several series of compounds designed based on the
Sulindac scaffold (as describedunderMethods). The scope of these studies was to probe the
effect of targeted modifications of this scaffold, the development of structure-activity relation-
ships, and the identification of analogs with the most potent inhibition of FtsZ polymerization
without affecting tubulin polymerization, coupled with potent whole cell antitubercular activ-
ity. Results of these studies are presented herein.
Whole cell antitubercular and cytotoxicity results. Fig 6 presents theMtbH37Rv and BJ
cell line cytotoxicity data of Sulindac sulfide amide derivatives 18–37. Compounds 18–23 with
basic acyclic acetamide linker at the C-3 position showed significant activity against the viru-
lent strain H37Rv. Among these six compounds, compound 22 with two n-butyl groups at the
terminal nitrogen was found to be more active than correspondingmethyl and ethyl substi-
tuted compounds. It is notable from the screening data of compounds 20 and 21 that the car-
bon chain length between the acetamide and the terminal nitrogen has marginal influence on
the activity. Either an additional substituent at the acetamide nitrogen or removal of a substitu-
ent from the terminal nitrogen did not improve the activity (19 and 23) dramatically. We also
Fig 5. Structures of a diverse set of compounds selected for screening.
doi:10.1371/journal.pone.0164100.g005
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explored the antibacterial activity of compounds with a basic cyclic acetamide group at the C-3
position (24–32). The compounds showed no significant activity against the BJ mammalian
cell line at the initial screening concentration similarly to results for the acyclic basic amide
analogs 18–23. Within this series, the piperidinylethyl analog 24 demonstrated the most signif-
icantMtb whole cell activity. The imidazol-1-ylpropyl analog 33 showed potent activity against
Fig 6. Mtb H37Rv and BJ cell data of Sulindac sulfide amide derivatives 18–37.
doi:10.1371/journal.pone.0164100.g006
Screening and Development of New FtsZ Inhibitors for M. Tuberculosis
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MtbH37Rv. The compounds with aromatic (34 and 35) or heteroaromatic (36) groups at the
acetamide linker are inactive in this assay. The activity of amino acid derivative 37mirrored
results for the acyclic and cyclic basic amides.
We then expanded our study to include a benzothiazol-2-ylmethylene group at the C-1
position (38–43, Fig 7) while varying the amide. These analogs demonstrated significant activ-
ity againstMtbH37Rv that was similar to their 4-methylthiobenzylidene analogs.
Fig 8 lists theMtbH37Rv and BJ cell data of α-methyl Sulindac sulfide amide derivatives 44–
55. Incorporation of a methyl group at the α-position of the amide group did not cause signifi-
cant alterations in activity. The N,N-dimethylaminoethyl analog 44 was 2-fold less active than its
desmethyl analog 18. The N,N’- dimethylaminoethyl acetamide derivative 48, in contrast, had
4-fold more activity than 23. In the case of the cyclic basic amide series, the α-methyl analogs dis-
played similar or slightly better activity than their corresponding desmethyl analogs.
We also prepared a small set of extended Sulindac sulfide amide derivatives 56–57 from 23
and 48 by coupling with L-Valine. The α-methyl analog 57 displayed an IC90 of 0.74 μM
against H37Rv, 6-fold more active than its desmethyl analog 56 (Fig 9).
Analogs exploring the amine linkage at the C-3 position are presented in Fig 10. Com-
pounds 58–59 with a benzyl or furan-2-ylmethyl linkage at the aminoethyl group at the C-3
position displayed excellent activity as compared to their inactive amide counterparts (34 and
36). The piperidinylethyl analog 60 also showed 1.6-fold more activity than its corresponding
amide analog 24.
Fig 7. Mtb H37Rv and BJ cell data of benzothiazolyl Sulindac amide derivatives 38–43.
doi:10.1371/journal.pone.0164100.g007
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Finally, we prepared a small set of related E-conformation compounds 61–63[31, 32] to fur-
ther test activity against whole bacteria andMtb FtsZ. These compounds and their activity are
reported in Fig 11. Comparison ofMtbH37Rv activity between compounds 18 and 61 suggests
no significant difference between the E and Z forms of this compound.
Activity of Sulindac Analogs againstMtb FtsZ and Tubulin. Selected compounds that
were available in sufficient quantities were examined for their ability to inhibit bothMtb FtsZ
and its mammalian homolog tubulin. The MIC forMtbH37Ra was also determined for this set.
Ten compounds demonstrated significant activity againstMtb FtsZ while not affecting tubulin
polymerization and these are reported in Table 2. It is notable that the H37Ra and H37Rv
(MIC99 versus IC90) data are relatively well correlated for these compounds.
To examine if the Sulindac analogs would also affect FtsZ polymerization in vivo, we utilized
aMtb FtsZ reporter strain,Mtb 41, wherein the FtsZ tagged with GFP serves as the sole source
of FtsZ. In this strain the chromosomal ftsZ gene is deleted and a copy of ftsZ-gfp expressed
from the inducible amidase promoter is integrated at the attB site.[38] Exponential cultures of
Fig 8. Mtb H37Rv and BJ cell data of α-methyl Sulindac sulfide amide derivatives 44–55.
doi:10.1371/journal.pone.0164100.g008
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Mtb 41 were exposed to 62 and 63 (75 μM) for 48 hours and the bacteria examined by bright-
field and fluorescencemicroscopy (Fig 12 –data are given for 63). Exposure to drug led to a
clear increase in bacterial cell length (Fig 12, compare panel a to c). In addition, distinct midcell
FtsZ-GFP rings seen in control cultures were absent in treated cultures (Fig 12, compare panel
b with d). Instead, the compound treated bacteria showed weak FtsZ-GFP fluorescent spots or
aggregates (Fig 12, panel d). Exposure to 62 and 63 also led to a similar growth inhibition ofM.
tuberculosis 41 (Fig 12B). Since FtsZ is essential for growth and viability ofMtb,[38] 62 and 63
inhibition of FtsZ ring assembly likely led to growth inhibition ofMtb 41.
ModelingMtb FtsZ inhibitor binding. Sulindac sulfide is a known human COX-1/COX-
2 inhibitor. Replacement of its carboxylate group with positively charged moieties such as N,
N-dimethylamino ethyl amide in compound 18 results in analogs that have greatly reduced
activity at COX-1/COX-2.[24] Tolerance and pharmacokinetic studies have shown that com-
pound 18 shows a greatly improved toxicity profile compared to Sulindac sulfide.[24]While
Fig 9. Mtb H37Rv and BJ cell data of extended Sulindac sulfide amide derivatives 56–57.
doi:10.1371/journal.pone.0164100.g009
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Sulindac sulfide is tolerated in mice up to 50 mg/kg over 20 days, compound 18 shows toler-
ance up to 300 mg/kg over 17 days. Also, compound 18maintains ~4 μM plasma levels for 8
hours after gastric gavage at a dosage of 200 mg/kg.[24] Compounds presented in Table 2 are
analogs of compound 18 containing the core substructure of Sulindac and positively charged
amine moieties and therefore may be expected to have favorable pharmacokinetic and toxicity
profiles as well. WhileMtb FtsZ inhibitory activities of the presented Sulindac analogs are mod-
erate, compounds from these series may serve as starting leads for the design of further chemi-
cal modifications to achieve better FtsZ inhibitory potencies. To provide insight into the
possible binding site of the presented compounds we modeled representative analogs and
known inhibitors from Table 1 into the crystal structure ofMtb FtsZ.
Fig 10. Mtb H37Rv and BJ cell data of Sulindac sulfide amine derivatives 58–60.
doi:10.1371/journal.pone.0164100.g010
Fig 11. Whole cell activity of three E-conformers 61–63.
doi:10.1371/journal.pone.0164100.g011
Screening and Development of New FtsZ Inhibitors for M. Tuberculosis
PLOS ONE | DOI:10.1371/journal.pone.0164100 October 21, 2016 13 / 23
Small molecule inhibitors may bind FtsZ in the GTP binding site or the interdomain cleft
region (Fig 13), which is equivalent to the Taxol binding region in tubulin and also contains
the co-crystallizedPC190723 in Staph. aureus FtsZ (PDB code 4DXD). These two sites have
been targeted in ligand binding studies of FtsZ inhibitor libraries.[47] Another pocket near
loop T7 has also been investigated recently in case of a B. subtilis FtsZ inhibitor, BT-benzo-29.
[48] Inhibitory effects of BT-benzo-29 on the assembly, GTPase activity of single mutant FtsZ
constructs compared to wild type provided evidence that residues L272, V275 play an impor-
tant role in the inhibition of FtsZ by this ligand. The corresponding residues in theMtb FtsZ
crystal structure (L269, I272, respectively) along with loop T7 define a new ligand binding site
that is distinct from the interdomain cleft site. Further, docking studies suggested that the FtsZ
inhibitors Scopoletin and CCR-11 may bind the same pocket.[49,50] InMtb FtsZ the corre-
sponding binding site is smaller compared to B. subtilis and we could not successfully dock
Table 2. Mtb FtsZ, tubulin and Mtb H37Ra and Rv data of selected Sulindac derivatives.
Compounds Mtb FtsZ Polymerizationa IC50 (μM) Tubulin Polymerizationa IC50 (μM) Mtb H37Rv IC90 (μM) Mtb H37Ra MIC99 (μg/mL)
18 39.4 ± 4.9 NA 7.29±0.23 8
19 42.3 ± 6.0 NA 6.67±0.14 16
23 34.9 ± 7.0 NA 8.28±0.33 8
24 26.5 ± 4.8 NA 1.41±0.03 >464
26 33.5 ± 5.9 NA 3.04±0.04 8
35 22.9 ± 4.8 NA >100* 64
56 38.0 ± 6.3 NA 4.34±0.06 8
61 44.6 ± 6.3 NA 7.70±0.33 16
62 43.3 ± 9.8 NA >100 32
63 37.6 ± 5.7 NA 25.48±0.33 32
aEach compound was analyzed at least three times per assay.
For the polymerization assays, the mean ± the standard deviations are reported.
NA = not active up to 100 μM.
*82% inhibition at 50 μM.
doi:10.1371/journal.pone.0164100.t002
Fig 12. Compounds 62 and 63 inhibit FtsZ ring assembly and growth of M.tuberculosis. (A) Exponential cultures of Mtb 41 grown without 63 (a, b) or
with 63 for 24 h (c, d) or 72 h (e, f) and imaged using brightfield (a, c, e) or fluorescent microscopy (b, d, f). Bar = 10 μms. Arrowhead–FtsZ-rings. Arrows–
aberrant FtsZ structures. (B) Exponential cultures of Mtb 41 in 7H9 broth (-) or (+) inhibitors for 5 d. A600 measured on days listed and plotted.
doi:10.1371/journal.pone.0164100.g012
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Sulindac analogs into this site although we cannot exclude the possibility that Sulindac analogs
may induce conformational changes of the T7 loop upon binding.
For docking Sulindac analogs we utilized theMtb FtsZ crystal structure (PDB code 1RLU)
and Induced Fit docking protocols (Schrödinger software), as detailed underMethods. Poses
Fig 13. Mtb FtsZ crystal structure (PDB code 1RLU). Co-crystallized GSP in the GTP binding site and
compound 24 docked into the interdomain cleft site are shown with carbons colored orange-brown.
doi:10.1371/journal.pone.0164100.g013
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docked into the interdomain cleft region showed more favorable interactions and better Glide
docking scores compared to poses docked into the GTP binding site. A representative analog
(24) from Table 2 docked into the interdomain cleft is illustrated in Figs 13 and 14A. Com-
pound 24 inhibitsMtb FtsZ polymerizationwith an IC50 of 26.5 μM and does not affect tubulin
polymerization up to 100 μM. Compound 24 is favorably accommodated in the interdomain
cleft binding site. The center of mass of the indene ring of compound 24 is at 4.0 Å distance
from the amine of Lys33 indicating aromatic–charge stabilizing interactions. The fluorine sub-
stituent on the indene ring predicts polar interactions with Thr200 and Thr199. The terminal
thiomethyl-benzene forms aromatic–positive charge contacts with Arg304 while the thio-
methyl participates in non-polar interactions with Leu188. Replacement of the phenyl ring
with a 4-pyridyl ring resulted in an inactive analog, consistent with the predicted loss of favor-
able interactions with Leu188. A 3,4,5-tri-OMe substitution introduced on the phenyl ring of
compound 24 renders the corresponding analog inactive againstMtb FtsZ. The docked pose of
24 suggests that the 3,4,5-tri-OMe substitution could not be accommodated because the phenyl
ring of 24 is ‘sandwiched’ betweenArg304 and backbone atoms of Gln30, with Gln192 in close
proximity. The piperidine ring of 24 participates in non-polar interactions with Ile295 and its
amine moiety salt bridges to Asp297. Other analogs listed in Table 2 containing a variety of
non-polar groups are accommodated in poses similar to that of 24. The varying non-polar
group in this series forms analogous, non-polar interactions with Ile295 while their positively
charged amine is salt bridging with Asp297. The similarity of the binding poses and analogous
non-polar interactions with Ile295 are consistent with our finding that these substitutions
resulted in only a modest variation ofMtb FtsZ polymerization inhibition, as IC50s range
between 22.9 and 44.6 μM within this series (Table 2).
Colchicine is a low potency inhibitor ofMtb FtsZ assembly at 104 μM and inhibits tubulin
assembly at 6.5 μM.[15]While the Colchicine binding pocket of tubulin has no structurally
analogous site inMtb FtsZ, our docking results predict that Colchicine can also be accommo-
dated in the interdomain cleft site of FtsZ. Similarities between the docked pose of compound
24 and Colchicine are illustrated in Fig 14B and 14C. Colchicine forms several favorable hydro-
gen bonding interactions with backbone atoms of Asp297, Ser298, Gly31, Lys33, and the side-
chain of Lys33. Binding poses of Colchicine and compound 24 displayed simultaneously in Fig
14C suggest that the indene of compound 24 and the Colchicine core ring structure occupy
overlapping space while the carbonyl and O-Me groups of the cyclohexyl moiety of Colchicine
Fig 14. Docked poses of (A) 24 (carbon atoms colored cyan) and (B) Colchicine (carbons colored orange).
All other atoms are colored by atom type (C green, O red, N blue, S yellow). H-bonds are indicated with dashed
lines. (C) Docked poses of 24 and Colchicine displayed simultaneously show overlap of similar pharmacophoric
features.
doi:10.1371/journal.pone.0164100.g014
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are in proximity to the amide carbonyl of analog 24, both ligands participating in similar
hydrogen bonding interactions with the D297 backbone.
Evidence supporting the interaction between inhibitors and residues in the interdomain
cleft binding site region has been presented in the case of several inhibitors. Table 3 lists exam-
ples, showing implicated amino acids and the corresponding residues as mapped onto theMtb
FtsZ crystal structure (PDB code 1RLU). The E. coli FtsZ residues R33, D187 and E305 (corre-
spondingMtb G31, E185, E302, respectively) are involved in the binding of doxorubicin
(Table 3). While G31 is in the interdomain cleft site, the other twoMtb FtsZ residues are
located near the boundary of the interdomain cleft site region on the side opposite to loop T7.
Ligands bound in the interdomain cleft side may possibly extend into this region near theMtb
residues E185, E302. Interestingly, a number of residues within the interdomain cleft binding
site have been implicated in functionalmotions that affect FtsZ polymerization and activity.
[51]
Out of the known FtsZ inhibitors from Table 1, we selected docked poses of five inhibitors
that occupy approximately overlapping regions with Sulindac analogs while sharing common
pharmacophoric features with the binding model of compound 24: Colchicine (1), Zantrin Z2
(8), AG-825 (15), ChemBridge 5481893 (12), and Quercetin (3). Description of Induced Fit
docked poses of the latter four inhibitors are provided under Supporting Information (S3
Appendix) and shown in the figure S1 Fig. Based on these five selected FtsZ inhibitors, a phar-
macophore model was developed describing average positions of atom groups that form analo-
gous interactions withMtb FtsZ by inhibitors within this set. The obtained composite
pharmacophore model may be utilized for the design of chemical modifications of the Sulindac
scaffold (or other ligands) to mimic predicted interactions formed by this set of FtsZ inhibitors.
A description and associated coordinates of the composite pharmacophore model are given in
Supporting Information (S4 Appendix). The model is illustrated and tabulated in figure S2 Fig
and S1 Table, respectively. The complete coordinates of the model are supplied in S4B
Appendix.
Conclusions
The series of compounds initially acquired and screenedwere selected based on established
antibacterial activity and/or reported bacterial FtsZ inhibition, as well as similarity to other
reported FtsZ inhibitors. All acquired samples were first screened in house againstMtb FtsZ
andMtbH37Ra and MAC NJ211, BSL-2 pathogens. Active samples were then tested against
tubulin polymerization for selectivity determination. Table 1 presents results obtained for a
number of compounds showing modest antitubercular activity versusMtbH37Ra, coupled
with activity against FtsZ in an IC50 range of about 20–50 μM. Results suggest further optimi-
zation strategies for some of these lead scaffolds that might improve FtsZ activity and poten-
tially concurrent antibacterial activity against the bacillus. The Tetracycline (Tetracycline– 5
and Minocycline– 6) class appears to show interesting activity against FtsZ, but the known pri-
mary target of this drug class is protein synthesis inhibition by binding the 30S ribosomal sub-
unit, while the FtsZ activity is likely only an interesting sideline.
Table 3. FtsZ interdomain cleft site region residues implicated in inhibitor binding.
Species Inhibitor Implicated FtsZ residues Corresponding Mtb residues Reference
Bacillus subtilis Plumbagin D199, V307 D196, R304 [52]
Bacillus cereus Cinnamaldehyde V208, G295 V206, G292 [53]
E. coli Doxorubicin R33, D187, E305 G31, E185, E302 [54]
doi:10.1371/journal.pone.0164100.t003
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Among the remaining actives, three in particular stand out for different reasons. First, Zan-
trin Z2 (compound 8) is approximately ten fold more potent against FtsZ than the range of
activity of most other FtsZ actives in Table 1 (20–50 μM). Furthermore, it has the best antibac-
terial activity in the set with an MIC99 of 1 μM againstMtbH37Ra while showing no activity
against tubulin up to 100 μM. Hence, we reasoned that initial results for this compound war-
ranted further evaluation, and a sample was screened in a mammalian cell line toxicity assay
(Vero cells) and a rapid PK model available through the NIH TAACF screening program.
Unfortunately (see S1 Appendix and Table A in S1 Appendix, in Supporting Information for
experimental details and results), Zantrin Z2 was equally toxic against Vero cells as it was active
againstMtbH37Ra. Furthermore, at the dose of 300 mg/kg in a rapid PK mouse model, the
sample showed no ill effects to the mice at a single dose but also showed no bioavailability by
oral gavage, suggesting that it is likely a poor development candidate.
Two other compounds (11 and 18) stood out from the remainder of the active samples as
purely synthetic molecules showing reasonable FtsZ activity and significant activity against
MtbH37Ra. Both compounds have advantages over the relatively more complex and less syn-
thetically tractable natural product scaffolds that showed activity in Table 1. Additionally,
Tamoxifen (11) is a clinically used agent suggesting reasonable starting bioavailability for a
lead pharmacophore, and compound 18 is a simple Sulindac analog that has been reported as
an active compound in vivo in a murine xenograft assay adapted for chemoprevention studies.
It is interesting to note that several 1,1,2-triarylethenesakin to Tamoxifen show significant
(nM) COX-2 activity,[55] demonstrating a plausible structural link of the NSAID Sulindac to
Tamoxifen and a basis for their similar FtsZ inhibition as well as suggesting that certain of the
related NSAIDs that effectively bind cyclooxygenasesmay have off-target FtsZ activity and
possibly, depending on substitution, tubulin. In many respects the two scaffolds are similar in
that they contain relatively planar aromatic ring systems with an attached basic amino function
that could be protonated at physiological pH, suggesting that a positively charged group may
be important for FtsZ activity. In fact, both of these features (aromaticity and cationic charac-
ter) are common features within the screening actives, and are important parts of the phamaco-
phore model developed in this program and discussed in this paper. While both samples
appear to be reasonable starting points for further SAR, we chose to focus this work on the
Sulindac scaffold due to our considerable experiencewith that template. In short, we prepared
a small series of Sulindac derivatives designed to test several substitution points on the scaffold.
New synthetic analogs were screened againstMtbH37Rv, and BJ cells (an immortalizedhuman
foreskin fibroblast cell line) for a preliminary assessment of overt cytotoxicity. Selected com-
pounds were also tested againstMtb FtsZ, its mammalian homolog tubulin andMtbH37Ra.
Several observations can bemade based on the modest SAR work. First, as a class, these com-
pounds show good, lead activity againstMtbH37Rv in vitro with certain analogs showing IC90
values below 1.0 μM. Although these compounds showed no activity in the BJ cell toxicity
assay at the modest screening cutoff, the Sulindac scaffold and analogs have been reported to
have mammalian cell cytotoxicity albeit givingmodest selectivity for cancer cell lines over nor-
mal cells in vitro.[24, 25] Finally, of the Sulindac analog set for which FtsZ activity was mea-
sured (Table 2), the H37Rv whole cell potency was consistently better thanMtb FtsZ inhibition
activity in this series, which might be due to cell wall penetration/transport issues as well as
possible activity at otherMtb targets. The difference betweenwhole cell and FtsZ activitiesmay
be specific to the core scaffold shared within this series, since for example another scaffold,
Zantrin Z2 shows about 10-fold more potent activity in the FtsZ assay than the average range
of these analogs. Furthermore, the inhibition in this Sulindac series is in a modest IC50 range of
approximately 23–45 μM in spite of the variety of substitutions, suggesting that we were not
Screening and Development of New FtsZ Inhibitors for M. Tuberculosis
PLOS ONE | DOI:10.1371/journal.pone.0164100 October 21, 2016 18 / 23
varying the structure enough to probe the true extent of the binding site pocket as demon-
strated by retrospective docking results of representative analogs of this series.
In order to test that these samples actually had a true effect on FtsZ polymerization under
normal bacterial growth conditions, we turned to the GFP-labeled Z-ring assay in Dr. Malini
Rajagopalan’s laboratory. In a GFP labeled FtsZ reporter strainMtb 41,[38] Sulindac analogs
62 and 63 showed significant growth inhibition at the MIC99 determined for those compounds
inMtbH37Ra. Furthermore, these growth effects translated into a clear visual inhibition of Z-
ring formation on analysis of the fluorescently labeled protein aggregation and ring formation
with time of exposure to both compounds. These results indicate that the Sulindac analogs 62
and 63 can have direct inhibitory effects on Z ring assembly, cell division and growth around
the determinedMIC99 in a related strainMtbH37Ra.
Our docking results suggest that Sulindac analogs target an interdomain cleft site which is
distinct from the GTP binding site inMtb FtsZ. The presented model offers rational
approaches to modify the scaffold to improve FtsZ binding through exploring this site more
extensively while potentially improvingMtb versus host cell selectivity (e.g. against tubulin and
off-target enzymes). Based on binding models of a structurally diverse set of known FtsZ inhib-
itors and their overlapping pharmacophoric features, we developed a composite pharmaco-
phore model that describes shared interactions present in the same active site region. Another
potential application is screening knownMtb phenotypic actives that are available on Pub-
Chem (http://www.ncbi.nlm.nih.gov/pcsubstance)[17,36]against the pharmacophore model
in order to identify other potential FtsZ inhibitor scaffolds with known selective activity versus
MtbH37Rv. Coordinates of this pharmacophore model are available (S4 Appendix, Supporting
Information) for future applications for the design of chemical modifications of inhibitor scaf-
folds for the improvement of their binding affinities. Overall, our observations indicate that
Sulindac derivatives remain a promising development scaffold for the design of new FtsZ
inhibitors againstM. tuberculosis. Promising analogs in the various series presented are candi-
dates for future medicinal chemistry optimization efforts and for further validation in follow-
up assays.
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S1 Appendix. Follow-up Screening of Zantrin Z2.
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S2 Appendix. Synthetic experimental details.Additional details on experimental synthetic
procedures.
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S3 Appendix. Description of docked poses of a selected set of FtsZ inhibitors utilized for
the development of the pharmacophoremodel.
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S4 Appendix. Pharmacophoremodel. (A) Description and (B) Cartesian coordinates.
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S1 Fig. Docked poses of Zantrin Z2, Quercetin, AG-825, ChemBridge 5481893 (compound
12) atMtb FtsZ. Carbons of the ligand are colored pink, all other atoms by atom type. H-
bonds are illustrated with dashed lines.
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S2 Fig. Pharmacophoremodel developedbased on five selectedMtb FtsZ inhibitors. (A)
Pharmacophore model sites are shown. Interactions with FtsZ residues are indicated with
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